Compounds that are ERK inhibitors

US8546404B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• Alan B. Cooper · West Caldwell, US
• Yongqi Deng · Newton, US
• Gerald W. Shipps, Jr. · Stoneham, US
• Neng-Yang Shih · Lexington, US
• Hugh Y. Zhu · Scotch Plains, US
• Robert Sun · Natick, US
• Joseph M. Kelly · Sayreville, US
• Ronald J. Doll · Maplewood, US
• Yang Nan · Nanjing, CN
• Tong Wang · Scottsdale, US
• Jagdish A. Desai · Manalapan, US
• James Wang · Newark, US
• Youhao Dong · Keasbey, US
• Vincent S. Madison · Mountain Lakes, US
• Li Xiao · Cranbury, US
• Alan Hruza · Hackettstown, US
• M. Arshad Siddiqui · Newton, US
• Ahmed Abdi Samatar · Plainsboro, US
• Sunil Paliwal · Manalapan, US
• Hon-Chung Tsui · East Brunswick Township, US
• Azim A. Celebi · Burlingame, US
• Yiji Wu · Scotch Plains, US
• Sobhana Babu Boga · Scotch Plains, US
• Abdul-Basit Alhassan · Scotch Plains, US
• Xiaolei Gao · Bound Brook, US
• Liang Zhu · Waltham, US
• Mehul Patel · Blue Bell, US

Key dates

• Filing date: Jun 5, 2007
• Grant date: Oct 1, 2013
• Expiry date: Nov 18, 2031

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/14
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Disclosed are the ERK inhibitors of formula 1.0:and the pharmaceutically acceptable salts, esters and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.